CHAL  |  Cardiovascular Health across the Lifespan Program

Leadership and Management

The Management Committee of the Cardiovascular Health Across the Lifespan Program (CHAL) is headed by the program leader, associate leader and manager. Membership also includes the Chief of Cardiology of the McGill University Health Centre (MUHC), three internal representatives from the Centre for Translational Biology (CTB) , the Centre for Innovative Medicine (CIM) and the Centre for Outcomes Research and Evaluation (CORE) , and one representative from another research program. The Management Committee seeks to expand the cardiovascular aspect of the CHAL program to include interdisciplinary experts performing cutting-edge translational biomedical research.


Dr. Ariane MarelliProgram Leader

Open postion, Associate Program Leader

Dr. Nadia GiannettiChief of Cardiology, MUHC

Dr. Louise PilotePopulation health representative (CORE)

Dr. Jacques GenestBasic research representative (CTB)

Dr. Mathias FriedrichClinical research representative (CIM)

Keith Murai, PhDExternal representative, Leader of the Brain Repair and Integrative Neuroscience (BRaIN) Program

Mohsen Damavandi, PhD, CHAL Program manager


Program leader and manager
Ariane Marelli, MD, is a professor of medicine at McGill University and the associate director, Research and Academic Affairs, for Cardiology at the McGill University Health Centre. She is an associate member of the Department of Epidemiology, Biostatistics and Occupational Health. Her research interests involve the impact of the changing epidemiology of congenital heart disease on health services delivery, quality and policy. Her research tools have included large administrative databases and electronic health records. She created and manages a population-based congenital heart disease database that covers over 100,000 patients with congenital heart disease from birth to old age in Quebec, from 1983 to 2010. Along with Dr. Jack Lewin, CEO of the American College of Cardiology, she was a first recipient of the 2011 Heart Heroes Award from the Adult Congenital Heart Association in recognition of "visionary leadership in epidemiology, quality of care and health IT for congenital heart disease patients." Her research is supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada and the Fonds de recherche du Québec−Santé (FRQS). She is a clinical research scholar of the FRQS.
Mohsen Damavandi, PhD, received his doctorate in kinesiology from the University of Montreal, and graduate diploma in Pharmaceutical and Healthcare Management and Innovation from Queen’s University. He has more than 15 years of research experience in the fields of musculoskeletal injuries and neuromuscular diseases in academia and healthcare industry. As a medical advisor fellow in inflammation and immunology at Pfizer Canada, he acquired experience in drug development and clinical trials monitoring. He has excellent communication, collaboration and scientific project management skills.